Clinical practice of renal cell carcinoma treatment with nivolumab

被引：0

作者：

Potocki, Pawel M. ^{[1
]}

Wysocki, Piotr J. ^{[1
]}

机构：

[1] Jagiellonian Univ, Coll Med, Dept Oncol, Krakow, Poland

来源：

ONCOLOGY IN CLINICAL PRACTICE | 2019年 / 15卷 / 05期

关键词：

kidney cancer; renal cell carcinoma; nivolumab; anti-PD-1; immunotherapy; checkpoint inhibitor; RANDOMIZED PHASE-3; CHECKMATE; 025; CANCER; EVEROLIMUS; IMMUNITY; SUNITINIB; BLOCKADE; EFFICACY; THERAPY; SAFETY;

D O I：

10.5603/OCP.2019.0002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nivolumab alike other immune checkpoint inhibitors has been intensively developed during the last decade. Kidney cancer is among the neoplasm in treatment of which we have accumulated the most experience regarding nivolumab. As improves our understanding of the mechanisms underlying specific cellular immune response, thus improves our understanding of the place the nivolumab holds among other therapeutic options. Recent years brought development of innovative immunotherapy combinations as a method for improving immunotherapy efficacy. This review aims at providing practicing oncologists with key aspects of renal cell carcinoma treatment with nivolumab.

引用

页码：237 / 245

页数：9

共 50 条

[21] The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice [J].

Raimondi, Alessandra ;

Randon, Giovanni ;

Sepe, Pierangela ;

Claps, Melanie ;

Verzoni, Elena ;

de Braud, Filippo ;

Procopio, Giuseppe .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (17)

[22] Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study [J].

Vano, Yann-Alexandre ;

Phan, Letuan ;

Gravis, Gwenaelle ;

Korakis, Iphigenie ;

Schlurmann, Friederike ;

Maillet, Denis ;

Bennamoun, Mostefa ;

Houede, Nadine ;

Topart, Delphine ;

Borchiellini, Delphine ;

Barthelemy, Philippe ;

Ratta, Raffaele ;

Ryckewaert, Thomas ;

Hasbini, Ali ;

Hans, Sophie ;

Emambux, Sheik ;

Cournier, Sandra ;

Braychenko, Elena ;

Elaidi, Reza-Thierry ;

Oudard, Stephane .

INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (08) :1335-1344

[23] Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study [J].

Blas, Leandro ;

Shiota, Masaki ;

Miyake, Hideaki ;

Takahashi, Masayuki ;

Oya, Mototsugu ;

Tsuchiya, Norihiko ;

Masumori, Naoya ;

Matsuyama, Hideyasu ;

Obara, Wataru ;

Shinohara, Nobuo ;

Fujimoto, Kiyohide ;

Nozawa, Masahiro ;

Ohba, Kojiro ;

Ohyama, Chikara ;

Hashine, Katsuyoshi ;

Akamatsu, Shusuke ;

Kamba, Tomomi ;

Mita, Koji ;

Gotoh, Momokazu ;

Tatarano, Shuichi ;

Fujisawa, Masato ;

Tomita, Yoshihiko ;

Mukai, Shoichiro ;

Ito, Keiichi ;

Tanegashima, Tokiyoshi ;

Tokunaga, Shoji ;

Eto, Masatoshi .

INTERNATIONAL JOURNAL OF UROLOGY, 2023, :788-796

[24] A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint [J].

Hizal, Mutlu ;

Sendur, Mehmet A. N. ;

Bilgin, Burak ;

Akinci, Muhammed Bulent ;

Dede, Didem Sener ;

Yalcin, Bulent .

CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (04) :625-635

[25] Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab [J].

Beulque, Yana ;

Kinget, Lisa ;

Roussel, Eduard ;

Mobaraki, Sajedeh ;

Laenen, Annouschka ;

Debruyne, Philip R. ;

Van Herck, Yannick ;

Baldewijns, Marcella ;

Wozniak, Agnieszka ;

Garg, Abhishek D. ;

Zucman-Rossi, Jessica ;

Couchy, Gabrielle ;

Albersen, Maarten ;

De Wever, Liesbeth ;

Haaker, Lorenz ;

Beuselinck, Benoit .

ACTA ONCOLOGICA, 2024, 63 :658-668

[26] Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date [J].

Sheng, Iris Y. ;

Ornstein, Moshe C. .

CANCER MANAGEMENT AND RESEARCH, 2020, 12 :4871-4881

[27] Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma [J].

Billon, Emilien ;

Walz, Jochen ;

Brunelle, Serge ;

Thomassin, Jeanne ;

Salem, Naji ;

Guerin, Mathilde ;

Vicier, Cecile ;

Dermeche, Slimane ;

Albiges, Laurence ;

Tantot, Florence ;

Nenan, Soazig ;

Pignot, Geraldine ;

Gravis, Gwenaelle .

FRONTIERS IN ONCOLOGY, 2019, 9

[28] Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study [J].

Tomita, Yoshihiko ;

Fukasawa, Satoshi ;

Shinohara, Nobuo ;

Kitamura, Hiroshi ;

Oya, Mototsugu ;

Eto, Masatoshi ;

Tanabe, Kazunari ;

Kimura, Go ;

Yonese, Junji ;

Yao, Masahiro ;

Motzer, Robert J. ;

Uemura, Hirotsugu ;

McHenry, M. Brent ;

Berghorn, Elmer ;

Ozono, Seiichiro .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (07) :639-646

[29] Nivolumab in treatment of renal cell carcinoma during renal replacement therapy [J].

Konopka, Kamil .

ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (01) :75-77

[30] Complete Remission of Bone Metastases in Renal Cell Carcinoma with Nivolumab [J].

Vuyyala, Sowjanya ;

Gandhi, Shipra ;

Kuechle, Joseph B. ;

George, Saby .

CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (08)

← 1 2 3 4 5 →